Keywords: genmab, gets, fast-track, humax-cd4, been, granted, priority

Genmab gets fast-track for HuMax-CD4

Article | 25 February 2002

Print This

Genmab has been granted a priority review in the USA for HuMax-CD4, thefirm's fully-human antibody in development for the treatment ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in